INSMED INC Cost of Revenue
INSMED INC (INSM) reported Cost of Revenue of $67.21 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-06
- INSMED INC cost of goods and services sold for the quarter ending 2026-06-30 was $67.21M, a 139.40% increase year-over-year.
- INSMED INC cost of goods and services sold for the quarter ending 2026-03-31 was $47.42M, a 122.86% increase year-over-year.
- INSMED INC cost of goods and services sold for the quarter ending 2025-12-31 was $44.22M, a 69.09% increase year-over-year.
- INSMED INC cost of goods and services sold for the quarter ending 2025-09-30 was $29.36M, a 38.71% increase year-over-year.
- INSMED INC cost of goods and services sold for fiscal 2025 was $122.94M, a 43.38% increase from fiscal 2024.
- INSMED INC cost of goods and services sold for fiscal 2024 was $85.74M, a 30.76% increase from fiscal 2023.
- INSMED INC cost of goods and services sold for fiscal 2023 was $65.57M, a 18.95% increase from fiscal 2022.
- INSMED INC cost of goods and services sold for fiscal 2022 was $55.13M, a 24.86% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $67.21M 10-Q · filed 2026-08-06 | $114.63M 10-Q · filed 2026-08-06 | $158.85M derived: sum of 3 quarters · filed 2026-08-06 | $188.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $47.42M 10-Q · filed 2026-05-07 | $91.64M derived: sum of 2 quarters · filed 2026-05-07 | $121.00M derived: sum of 3 quarters · filed 2026-05-07 | $149.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $44.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $73.58M derived: sum of 2 quarters · filed 2026-02-19 | $101.66M derived: sum of 3 quarters · filed 2026-08-06 | $122.94M 10-K · filed 2026-02-19 |
| 2025-09-30 | $29.36M 10-Q · filed 2025-10-30 | $57.44M derived: sum of 2 quarters · filed 2026-08-06 | $78.72M 10-Q · filed 2025-10-30 | $104.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $28.07M 10-Q · filed 2026-08-06 | $49.35M 10-Q · filed 2026-08-06 | $75.50M derived: sum of 3 quarters · filed 2026-08-06 | $96.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $21.28M 10-Q · filed 2026-05-07 | $47.43M derived: sum of 2 quarters · filed 2026-05-07 | $68.60M derived: sum of 3 quarters · filed 2026-05-07 | $89.56M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $26.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $47.32M derived: sum of 2 quarters · filed 2026-02-19 | $68.28M derived: sum of 3 quarters · filed 2026-02-19 | $85.74M 10-K · filed 2026-02-19 |
| 2024-09-30 | $21.17M 10-Q · filed 2025-10-30 | $42.13M derived: sum of 2 quarters · filed 2025-10-30 | $59.59M 10-Q · filed 2025-10-30 | $78.03M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $20.96M 10-Q · filed 2025-08-07 | $38.42M 10-Q · filed 2025-08-07 | $56.86M derived: sum of 3 quarters · filed 2026-02-19 | $73.57M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $17.46M 10-Q · filed 2025-05-08 | $35.90M derived: sum of 2 quarters · filed 2026-02-19 | $52.61M derived: sum of 3 quarters · filed 2026-02-19 | $69.20M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $18.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $35.15M derived: sum of 2 quarters · filed 2026-02-19 | $51.74M derived: sum of 3 quarters · filed 2026-02-19 | $65.57M 10-K · filed 2026-02-19 |
| 2023-09-30 | $16.71M 10-Q · filed 2024-10-31 | $33.30M derived: sum of 2 quarters · filed 2024-10-31 | $47.13M 10-Q · filed 2024-10-31 | $60.20M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $16.59M 10-Q · filed 2024-08-08 | $30.42M 10-Q · filed 2024-08-08 | $43.49M derived: sum of 3 quarters · filed 2025-02-20 | $56.96M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $13.83M 10-Q · filed 2024-05-09 | $26.90M derived: sum of 2 quarters · filed 2025-02-20 | $40.37M derived: sum of 3 quarters · filed 2025-02-20 | $56.77M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $13.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $26.54M derived: sum of 2 quarters · filed 2025-02-20 | $42.94M derived: sum of 3 quarters · filed 2025-02-20 | $55.13M 10-K · filed 2025-02-20 |
| 2022-09-30 | $13.47M 10-Q · filed 2023-10-26 | $29.87M derived: sum of 2 quarters · filed 2023-10-26 | $42.06M 10-Q · filed 2023-10-26 | $55.34M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $16.39M 10-Q · filed 2023-08-03 | $28.59M 10-Q · filed 2023-08-03 | $41.87M derived: sum of 3 quarters · filed 2024-02-22 | $52.06M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $12.19M 10-Q · filed 2023-05-04 | $25.48M derived: sum of 2 quarters · filed 2024-02-22 | $35.66M derived: sum of 3 quarters · filed 2024-02-22 | $46.50M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $13.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $23.47M derived: sum of 2 quarters · filed 2024-02-22 | $34.31M derived: sum of 3 quarters · filed 2024-02-22 | $44.15M 10-K · filed 2024-02-22 |
| 2021-09-30 | $10.18M 10-Q · filed 2022-10-27 | $21.02M derived: sum of 2 quarters · filed 2022-10-27 | $30.86M 10-Q · filed 2022-10-27 | $41.73M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $10.84M 10-Q · filed 2022-08-04 | $20.68M 10-Q · filed 2022-08-04 | $31.54M derived: sum of 3 quarters · filed 2023-02-23 | $42.16M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $9.84M 10-Q · filed 2022-05-05 | $20.71M derived: sum of 2 quarters · filed 2023-02-23 | $31.33M derived: sum of 3 quarters · filed 2023-02-23 | $41.28M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $10.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $21.48M derived: sum of 2 quarters · filed 2023-02-23 | $31.43M derived: sum of 3 quarters · filed 2023-02-23 | $39.87M 10-K · filed 2023-02-23 |
| 2020-09-30 | $10.62M 10-Q · filed 2021-10-28 | $20.57M derived: sum of 2 quarters · filed 2021-10-28 | $29.01M 10-Q · filed 2021-10-28 | $37.72M derived: sum of 4 quarters · filed 2022-02-17 |
| 2020-06-30 | $9.95M 10-Q · filed 2021-08-05 | $18.39M 10-Q · filed 2021-08-05 | $27.09M derived: sum of 3 quarters · filed 2022-02-17 | $33.53M derived: sum of 4 quarters · filed 2022-02-17 |
| 2020-03-31 | $8.44M 10-Q · filed 2021-05-06 | $17.14M derived: sum of 2 quarters · filed 2022-02-17 | $23.58M derived: sum of 3 quarters · filed 2022-02-17 | $28.50M derived: sum of 4 quarters · filed 2022-02-17 |
| 2019-12-31 | $8.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $15.14M derived: sum of 2 quarters · filed 2022-02-17 | $20.06M derived: sum of 3 quarters · filed 2022-02-17 | $24.21M 10-K · filed 2022-02-17 |
| 2019-09-30 | $6.44M 10-Q · filed 2020-10-29 | $11.36M derived: sum of 2 quarters · filed 2020-10-29 | $15.51M 10-Q · filed 2020-10-29 | $17.93M derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-06-30 | $4.92M 10-Q · filed 2020-08-06 | $9.07M 10-Q · filed 2020-08-06 | $11.49M derived: sum of 3 quarters · filed 2020-08-06 | $11.49M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $4.15M 10-Q · filed 2020-04-30 | $6.57M derived: sum of 2 quarters · filed 2020-04-30 | $6.57M derived: sum of 3 quarters · filed 2020-04-30 | $6.57M derived: sum of 4 quarters · filed 2020-04-30 |
| 2018-12-31 | $2.42M 10-K · filed 2019-02-22 | $2.42M derived: sum of 2 quarters · filed 2019-10-30 | $2.42M derived: sum of 3 quarters · filed 2019-10-30 | $2.42M 10-K · filed 2021-02-25 |
| 2018-09-30 | $0.00 10-Q · filed 2019-10-30 | $0.00 derived: sum of 2 quarters · filed 2019-10-30 | $0.00 10-Q · filed 2019-10-30 | $0.00 derived: sum of 4 quarters · filed 2019-10-30 |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-01 | $0.00 10-Q · filed 2019-08-01 | $0.00 derived: sum of 3 quarters · filed 2019-08-01 | $0.00 derived: sum of 4 quarters · filed 2019-08-01 |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-07 | $0.00 derived: sum of 2 quarters · filed 2019-05-07 | $0.00 derived: sum of 3 quarters · filed 2019-05-07 | $0.00 derived: sum of 4 quarters · filed 2019-05-07 |
| 2017-12-31 | $0.00 10-K · filed 2019-02-22 | $0.00 derived: sum of 2 quarters · filed 2019-02-22 | $0.00 derived: sum of 3 quarters · filed 2019-02-22 | $0.00 10-K · filed 2020-02-25 |
| 2017-09-30 | $0.00 10-K · filed 2019-02-22 | $0.00 derived: sum of 2 quarters · filed 2019-02-22 | $0.00 derived: sum of 3 quarters · filed 2019-02-22 | |
| 2017-06-30 | $0.00 10-K · filed 2019-02-22 | $0.00 derived: sum of 2 quarters · filed 2019-02-22 | ||
| 2017-03-31 | $0.00 10-K · filed 2019-02-22 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |